COPENHAGEN, Denmark–(BUSINESS WIRE)–Nordic Capital, a number one international healthcare personal fairness investor, invests in LEO Pharma and turns into an lively minority proprietor and accomplice to the LEO Basis. The funding will help LEO Pharma on its journey to strengthening its international management in medical dermatology and assist speed up innovation and development. The LEO Basis will stay the corporate’s majority proprietor.
In 2020, LEO Pharma launched its 2030 technique with the ambition to be a worldwide chief in medical dermatology by increasing its main branded topical dermatology franchise and growing a deep, progressive pipeline. To help the corporate’s long-term targets and bold development technique, the LEO Basis now welcomes Nordic Capital as a brand new lively minority proprietor. Nordic Capital will make investments EUR 450 million in LEO Pharma and help the 2030 technique in partnership with the LEO Basis who will stay the corporate’s majority shareholder.
“The partnership with Nordic Capital is a powerful affirmation that LEO Pharma is an distinctive firm with a beneficial heritage in topical dermatology that has clear potential to develop into a frontrunner in progressive therapies,” stated Jesper Mailind, CEO of the LEO Basis. “I’m very enthusiastic in regards to the alternative to welcome Nordic Capital onboard. With Nordic Capital now we have secured a supportive and seasoned accomplice going ahead with deep medical experience and a powerful observe document supporting worth creation in progressive healthcare companies globally. Additional, their sturdy Scandinavian heritage lends itself to a standard cultural understanding and strategy. I’m assured that the partnership will additional improve the appreciable development potential of LEO Pharma, and it’s a pure subsequent step on LEO Pharma’s journey.”
Nordic Capital is without doubt one of the most lively and skilled traders in healthcare globally. The agency has a powerful observe document of investing in progressive corporations and constructing business leaders in shut partnership with administration groups and co-owners. Since inception in 1989, Nordic Capital has invested greater than EUR 7 billion in 29 healthcare investments throughout Europe and North America. Inside prescribed drugs, Nordic Capital’s present and former investments embody Acino, Nycomed, Fougera, Biovitrum and Meda. As we speak, Nordic Capital has 14 portfolio corporations within the broader healthcare sector with c. 44,000 workers and combination revenues in extra of EUR 6 bn.
“We couldn’t be extra happy that Nordic Capital is partnering with the LEO Basis and LEO Pharma,” stated Jonas Agnblad, Accomplice, Co-Head of Healthcare, Nordic Capital Advisors. “Dermatology is without doubt one of the quickest rising therapeutic areas inside prescribed drugs. We see scientific advances addressing important unmet wants within the coming years, leading to super worth for sufferers and healthcare techniques. Nordic Capital shares the LEO Basis’s and administration’s imaginative and prescient and technique for LEO Pharma. That technique delivers development by way of thrilling upcoming progressive product launches in addition to continued deal with the market-leading established product portfolio. It is a mixture that we consider will ship sturdy development and alternative sooner or later.”
Catherine Mazzacco, CEO of LEO Pharma, stated: “I’m delighted to welcome Nordic Capital as our new co-owner and accomplice in our formidable endeavors to make LEO Pharma a worldwide chief in medical dermatology. I’m assured that we, with our new possession mannequin, have paved the way in which for additional acceleration of our sturdy development ambitions, and that it will allow us to additional strengthen our dedication to dermatology, with a sustained deal with constructing a powerful pipeline and innovating throughout science and expertise to the advantage of sufferers.”
The transaction is topic to customary regulatory approvals and completion is predicted to happen within the first half of 2021. The phrases of the transaction weren’t disclosed.
Moelis & Firm acted as monetary advisor and Plesner acted as authorized advisor to the LEO Basis and LEO Pharma. BofA Securities acted as monetary advisor and Accura acted as authorized advisor to Nordic Capital.
About LEO Pharma
The corporate is a frontrunner in medical dermatology with a strong R&D pipeline, a variety of therapies and a pioneering spirit. Based in 1908, LEO Pharma has devoted a long time of analysis and growth to advance the science of dermatology, setting new requirements of take care of folks with pores and skin situations. LEO Pharma is headquartered in Denmark with a worldwide staff of 6,000 folks, serving 93 million sufferers in additional than 130 nations.
For extra details about LEO Pharma, please go to: www.leo-pharma.com
About Nordic Capital
Nordic Capital is a number one personal fairness investor with a resolute dedication to creating stronger, sustainable companies by way of operational enchancment and transformative development. Nordic Capital focuses on chosen areas and sectors the place it has deep expertise and an extended historical past. Focus sectors are Healthcare, Expertise & Funds, Monetary Companies, and selectively, Industrial & Enterprise Companies. Key areas are Europe and globally for Healthcare and Expertise & Funds investments. Since inception in 1989, Nordic Capital has invested EUR 16 billion in over 110 investments. Nordic Capital Advisors have native workplaces in Sweden, Denmark, Finland, Norway, Germany, the U.Okay. and the U.S.
For extra details about Nordic Capital, please go to: www.nordiccapital.com
Footnote: “Nordic Capital” refers to any, or all, Nordic Capital branded funds and autos and related entities. The overall companions of Nordic Capital’s funds and autos are suggested by a number of non-discretionary sub-advisory entities, all or any of which is known as “Nordic Capital Advisors”.
Concerning the LEO Basis
The LEO Basis is one in all Denmark’s largest business foundations and an engaged proprietor of the pharmaceutical firm LEO Pharma. The Basis’s essential goal is to make sure the corporate’s long-term growth and success. In addition to the possession, the Basis offers philanthropic grants with the goal to help the perfect worldwide analysis in pores and skin illnesses and make Denmark a worldwide beacon for pores and skin analysis.
For extra details about the LEO Basis, please go to: www.leo-foundation.org
